# Mike Lee (investor)
Michael (Mike) Lee is a biotechnology investor who co-founded the Redmile Group in 2007 and serves as one of its portfolio managers; he is also named on the SEC Form D filings of Redmile's Redmile Biopharma Investments funds as an executive officer of the general partner.[1](https://igmbio.com/team/michael-lee/) • [2](https://aum13f.com/person/mike-lee) Redmile is a health care-focused investment firm based in San Francisco and New York.[3](https://www.fatetherapeutics.com/michael-lee/) Lee sits on the boards of three publicly traded biotech companies, Fate Therapeutics, IGM Biosciences, and [Shattuck Labs](https://www.edgepedia.org/shattuck-labs).[1](https://igmbio.com/team/michael-lee/) He should not be confused with other people named Mike or Michael Lee; the record described here is anchored to the Redmile co-founder named in board biographies and Redmile fund filings.
| Fact | Detail |
|---|---|
| Firm | Redmile Group, LLC, a health care-focused investment firm in San Francisco and New York[3](https://www.fatetherapeutics.com/michael-lee/) |
| Role | Co-Founder and Portfolio Manager since 2007; Bloomberg lists him as Managing Director/Co-Founder[1](https://igmbio.com/team/michael-lee/) • [4](https://www.bloomberg.com/profile/person/16684069) |
| Fund filings | Executive Officer on Redmile Biopharma Investments II LP ($675.4M) and III LP ($500.2M), Redco II Master Fund LP ($1,555.9M aggregate), and Redmile Growth Investments I LP ($122.0M)[2](https://aum13f.com/person/mike-lee) |
| Earlier roles | Biotechnology investor at Steeple Capital; analyst at Welch Capital Partners and Prudential Equity Group[1](https://igmbio.com/team/michael-lee/) |
| Education | B.S. in Molecular and Cellular Biology, University of Arizona[1](https://igmbio.com/team/michael-lee/) |
| Board seats | Fate Therapeutics (since July 2018), IGM Biosciences (since July 2019), Shattuck Labs (since June 2020)[1](https://igmbio.com/team/michael-lee/) |
## Career and education
Lee's path into biotech investing combined a science degree with equity-research and investment roles. He holds a B.S. in Molecular and Cellular Biology from the [University of Arizona](https://www.edgepedia.org/university-of-arizona), a background that underpins his career in health care and biotechnology investing.[1](https://igmbio.com/team/michael-lee/)
Before founding Redmile, Lee worked as a biotechnology investor at Steeple Capital, an investment management firm, and as an analyst at Welch Capital Partners, an investment advisory firm, and at Prudential Equity Group.[1](https://igmbio.com/team/michael-lee/)
In 2007 Lee co-founded Redmile Group and became one of its portfolio managers.[1](https://igmbio.com/team/michael-lee/) Bloomberg's profile lists him as Managing Director and Co-Founder of Redmile Group LLC; the board biographies use Co-Founder and Portfolio Manager, so his title is described by both sources rather than fixed to one label.[1](https://igmbio.com/team/michael-lee/) • [4](https://www.bloomberg.com/profile/person/16684069)
## Redmile and the Biopharma Investments funds, by the numbers
Redmile raises dedicated private vehicles, the [Redmile Biopharma Investments](https://www.edgepedia.org/redmile-biopharma-investments) series, alongside its advisory business, and SEC Form D filings give the clearest picture of the firm's scale. Lee appears as an executive officer on the filings for Redmile Biopharma Investments II LP, which raised $675.4 million, and Redmile Biopharma Investments III LP, which raised $500.2 million against $1,133.8 million in aggregate; he is also listed as an executive officer of Redco II Master Fund LP, showing $31.4 million raised and $1,555.9 million in aggregate, and of Redmile Growth Investments I LP, which raised $122.0 million against $137.0 million in aggregate.[2](https://aum13f.com/person/mike-lee) Earlier filings list him as a promoter of Redmile Biopharma Investments I LP, which raised $218.3 million, and Redmile Private Investments II LP, which raised $131.2 million; the filing record spans 2011 through 2026.[2](https://aum13f.com/person/mike-lee)
The filings establish his listing as an executive officer or promoter on each vehicle; no source describes the specific powers the role carries.
## Boards and public positions
Lee holds three board seats. He has served on the board of Fate Therapeutics, a biopharmaceutical company, since July 2018; on the board of IGM Biosciences since July 2019; and on the board of Shattuck Labs, a biotechnology company, since June 2020.[1](https://igmbio.com/team/michael-lee/) His director listing on Shattuck Labs' own Form D filing, which reports $83.0 million raised, corroborates the Shattuck seat.[2](https://aum13f.com/person/mike-lee)
## References
1. [Michael Lee - IGM Biosciences board of directors](https://igmbio.com/team/michael-lee/)
2. [Mike Lee | AUM 13F](https://aum13f.com/person/mike-lee)
3. [Michael Lee - Fate Therapeutics](https://www.fatetherapeutics.com/michael-lee/)
4. [Michael Lee, Redmile Group LLC: Profile and Biography - Bloomberg Markets](https://www.bloomberg.com/profile/person/16684069)
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles K to Z*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license